Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent eventsEffective November 12, 2022, the Company's Board of Directors approved a strategic decision to discontinue further development of NL-201, and to move forward focusing the Company's investment in early stage pre-clinical development of the next generation of de novo proteins. The Board of Directors also approved a restructuring plan, including a reduction in force of approximately 40%. The Company's current best estimate of costs it will incur total between $6.3 million and $8.3 million, consisting of severance, benefits, costs associated with the discontinuation of further development of NL-201, and other costs. The majority of these costs are expected to be incurred during the fourth calendar quarter of 2022 and the first half of 2023, and the Company expects the execution of the restructuring plan will be substantially complete by the second calendar quarter of 2023.